TREX1 and infection: By contrast, infected mice treated with the fusogenic targeted NP delivering the siIrf5 therapeutic (F-siIRF5-CRV) demonstrated a notable decrease in titer starting 2 days post infection and titers reached the baseline count at 8 days post infection.